Sera Sees PreTRM Test Volume Rise Fivefold
The company's third-quarter 2026 earnings call highlighted growing adoption of its PreTRM test and expanded state Medicaid coverage in Florida and Illinois.
Updated on Nov. 16, 2026 in Public Companies

Live Poll
Do you think expanding Medicaid coverage should include newer prenatal blood tests?
Sera reported that test volume for its PreTRM test increased approximately fivefold from the first quarter of 2026, according to its third-quarter 2026 earnings call on November 4, 2026. The growth coincided with Florida and Illinois expanding state Medicaid coverage for the test.
Why it matters
State Medicaid programs pay for roughly 40% to 43% of U.S. births, making coverage decisions a major factor in whether new prenatal tests reach patients at scale. Physician adoption is also central, as Sera's commercial sales depend on converting initial awareness into routine clinical practice.
Sera reported a fivefold increase in PreTRM test volume since Q1 2026, with the company holding $72.8 million in cash and 4 active pilot programs, two of them with major national health plans. Whether the volume gain holds as physician adoption continues to build over the next 12 to 18 months remains unclear.
The players
Sera
Sera is the company that markets the PreTRM test and reports on its commercial rollout, pilot programs and state Medicaid coverage.
The details
Sera said commercial sales depend on active field education and electronic record integrations that help physicians move from initial awareness to routine use, a transition the company says has taken 12 to 18 months. Paid pilot trials with large private insurers are generating health economic data, and Florida, with nearly 90,000 Medicaid births and approximately 4 million Medicaid lives, is among the states that expanded coverage.
Timeline
Q1 2026: Baseline test volume for PreTRM was measured.
November 4, 2026: Sera reported on its third-quarter 2026 earnings call that volume had increased.
2027: Operating expenses are expected to stay flat or decline, and a potential multistate implementation with a large managed care organization is anticipated.
Fiscal year 2029: Sera's current cash is expected to fund operations through this year.
Market Landscape
State Medicaid programs pay for roughly 40% to 43% of U.S. births, so the Florida and Illinois coverage expansions place PreTRM inside one of the largest public payer channels in prenatal care. The company's push toward multistate implementation with a major managed care organization would extend that position across additional state markets.
Expanded Medicaid coverage in Florida and Illinois means eligible patients in those states may have access to PreTRM testing without paying out of pocket. Broader adoption in 2027 could extend that access to additional states if the planned multistate implementation proceeds.
The takeaway
Expanding public coverage and physician adoption are the two levers that will determine whether PreTRM's early growth becomes sustained commercial scale. Readers tracking the company should watch whether the 2027 multistate rollout materializes.
What happens next
Sera expects a potential multistate 2027 implementation with one of the nation's largest managed care organizations and plans kit-based international expansion by 2027.
Further reading
Follow more company earnings and corporate developments in Public Companies.
Source note: This article includes information reported by The Motley Fool.
Live Poll
Do you think expanding Medicaid coverage should include newer prenatal blood tests?





